ATE359358T1 - Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden - Google Patents

Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden

Info

Publication number
ATE359358T1
ATE359358T1 AT03764511T AT03764511T ATE359358T1 AT E359358 T1 ATE359358 T1 AT E359358T1 AT 03764511 T AT03764511 T AT 03764511T AT 03764511 T AT03764511 T AT 03764511T AT E359358 T1 ATE359358 T1 AT E359358T1
Authority
AT
Austria
Prior art keywords
cells
media
sialylysis
controlling
proteins produced
Prior art date
Application number
AT03764511T
Other languages
English (en)
Inventor
Brian D Follstad
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE359358T1 publication Critical patent/ATE359358T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins

Landscapes

  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT03764511T 2002-07-15 2003-07-14 Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden ATE359358T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39622102P 2002-07-15 2002-07-15

Publications (1)

Publication Number Publication Date
ATE359358T1 true ATE359358T1 (de) 2007-05-15

Family

ID=30115987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03764511T ATE359358T1 (de) 2002-07-15 2003-07-14 Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden

Country Status (15)

Country Link
US (1) US7645609B2 (de)
EP (1) EP1543106B1 (de)
JP (1) JP4510938B2 (de)
AT (1) ATE359358T1 (de)
AU (1) AU2003249055B2 (de)
CA (1) CA2492267C (de)
CY (1) CY1107689T1 (de)
DE (1) DE60313188T2 (de)
DK (1) DK1543106T3 (de)
ES (1) ES2285188T3 (de)
MX (1) MXPA05000552A (de)
PL (1) PL376381A1 (de)
PT (1) PT1543106E (de)
SI (1) SI1543106T1 (de)
WO (1) WO2004008100A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335024D1 (de) 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
WO2007047687A2 (en) * 2005-10-14 2007-04-26 Zymequest, Inc. Compositions and methods for prolonging survival of platelets
ES2376777T3 (es) * 2004-09-07 2012-03-16 Velico Medical, Inc. Aparato para prolongar la supervivencia de plaquetas
JP5123663B2 (ja) * 2004-10-15 2013-01-23 ベリコ メディカル インコーポレイティッド 血小板の生存延長のための組成物および方法
EP1910542B1 (de) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
EP1937306B1 (de) * 2005-08-19 2016-02-17 Janssen Biotech, Inc. Proteolyse-resistente antikörperzubereitungen
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP2253644B1 (de) * 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Zusammensetzungen und Verfahren zur Herstellung einer Zusammensetzung
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TWI456062B (zh) 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
JP5634710B2 (ja) * 2007-03-19 2014-12-03 国立大学法人 岡山大学 タンパク質産生用およびウイルス増殖用の培地
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
EP2233502A1 (de) * 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(vWF)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
AU2010319327B2 (en) 2009-11-13 2015-08-13 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
EP2325296A1 (de) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Herstellung von Glykoproteinen mit niedrigem N-Glykolylneuraminsäure-Gehalt (Neu5Gc-Gehalt)
EP2512501A4 (de) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc Haarwuchsverfahren unter verwendung extrazellulärer fgfr3-domänen
US9428727B2 (en) 2010-04-26 2016-08-30 Novartis Ag Cell culture medium
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
BR112014000352A2 (pt) 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
JP2015505818A (ja) 2011-11-14 2015-02-26 ファイブ プライム セラピューティックス インコーポレイテッド 癌を治療する方法
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG11201507875RA (en) * 2013-03-26 2015-10-29 Coherus Biosciences Inc Protein production method
US9481901B2 (en) * 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PE20161417A1 (es) * 2014-03-05 2017-01-22 Ultragenyx Pharmaceutical Inc Composiciones de glicoproteinas sialiladas y uso de estas
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
CA3005906A1 (en) 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
HRP20250618T1 (hr) 2018-07-03 2025-07-18 Gilead Sciences, Inc. Protutijela koja ciljaju na hiv gp120 i postupci za uporabu
CN119080940A (zh) 2018-12-21 2024-12-06 杭州景杰生物科技股份有限公司 蛋白质赖氨酸乳酸酰化检测试剂和用途
WO2022140389A1 (en) 2020-12-22 2022-06-30 Amgen Inc. Cell culture method
EP4301333A2 (de) 2021-03-03 2024-01-10 Formycon AG Formulierungen von ace2-fc-fusionsproteinen
US20250027067A1 (en) 2021-11-24 2025-01-23 Formycon Ag Improved ace2 fusion proteins
CN114317446B (zh) * 2021-12-30 2023-12-05 广州康盛生物科技股份有限公司 一种无血清培养基用添加剂及其应用
EP4331571A1 (de) 2022-09-02 2024-03-06 Formycon AG Formulierungen von ace2-igm-fusionsproteinen
EP4386084A1 (de) 2022-12-14 2024-06-19 Formycon AG Verbesserte ace2-fusionsproteine
WO2025038362A1 (en) 2023-08-11 2025-02-20 Merck Sharp & Dohme Llc Monovalent interleukin 12 (il-12) heterodimeric fc proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
JP3375140B2 (ja) 1991-03-08 2003-02-10 森永製菓株式会社 モノクローナル抗体生産用培地の作製法及びそのキット
DE69311873T2 (de) * 1992-05-01 1998-02-12 Teijin Ltd Fed-batch-Verfahren für Proteine sekretierende Zellen
JPH06292592A (ja) * 1993-02-09 1994-10-21 Snow Brand Milk Prod Co Ltd 糖蛋白質の生産方法
US5858783A (en) * 1993-05-25 1999-01-12 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Production of normal mammalian organ culture using a medium containing mem-alpha, leibovitz L-15, glucose galactose fructose
EP1659173A1 (de) * 1997-10-01 2006-05-24 DSMIP Assets B.V. Verfahren zur Protein-Herstellung
ES2523599T3 (es) 1997-12-03 2014-11-27 Roche Diagnostics Gmbh Eritropoyetina de gran actividad específica
ES2252876T5 (es) * 1997-12-03 2014-04-03 Roche Diagnostics Gmbh Proceso para preparar polipéptidos con glicolización adecuada
AU5339699A (en) * 1998-08-06 2000-02-28 Johns Hopkins University School Of Medicine, The Compounds for altering cell surface sialic acids and methods of use therefor
DE19852729A1 (de) 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
US6949372B2 (en) * 1999-03-02 2005-09-27 The Johns Hopkins University Engineering intracellular sialylation pathways
US6261805B1 (en) * 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
AU2001271021A1 (en) * 2000-07-05 2002-01-14 Japan As Represented By Secretary Of Osaka University Process for producing glycoprotein
US20040214228A9 (en) * 2001-09-14 2004-10-28 Ganesh Venkataraman Methods of evaluating glycomolecules for enhanced activities
JP4281797B2 (ja) 2006-12-21 2009-06-17 三菱自動車工業株式会社 車両の車体構造

Also Published As

Publication number Publication date
CA2492267C (en) 2013-09-10
EP1543106A4 (de) 2005-08-10
PT1543106E (pt) 2007-05-31
WO2004008100A3 (en) 2004-03-25
SI1543106T1 (sl) 2007-08-31
CA2492267A1 (en) 2004-01-22
US20040115768A1 (en) 2004-06-17
JP4510938B2 (ja) 2010-07-28
AU2003249055A1 (en) 2004-02-02
EP1543106B1 (de) 2007-04-11
DE60313188D1 (de) 2007-05-24
EP1543106A2 (de) 2005-06-22
DK1543106T3 (da) 2007-08-13
DE60313188T2 (de) 2007-12-20
MXPA05000552A (es) 2005-04-28
WO2004008100A2 (en) 2004-01-22
AU2003249055B2 (en) 2008-06-26
JP2005532813A (ja) 2005-11-04
ES2285188T3 (es) 2007-11-16
US7645609B2 (en) 2010-01-12
CY1107689T1 (el) 2013-04-18
PL376381A1 (en) 2005-12-27

Similar Documents

Publication Publication Date Title
ATE359358T1 (de) Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden
EP1360314A4 (de) Chemisch definiertes medium für kultivierte säugerzellen
DE69939901D1 (de) Verfahren und materialien zur herstellung von glucosamin
ATE405644T1 (de) Verfahren zur herstellung und reinigung von erythropoietin
BR0311413A (pt) Desenvolvimento e transdiferenciação de células acinares humanas
DE502004008542D1 (de) Verfahren zur reklonierung von produktionszellen
NO973801L (no) Nye proteiner og fremgangsmåter for fremstilling av proteinene
ATE430807T1 (de) Verfahren zur kultivierung von circovirus
DE60323468D1 (de) Vögelzell-linien und deren verwendung zur herstellung interessanter biologischer substanzen
ATE517996T1 (de) Verfahren und mittel zur erhöhung der toleranz von pflanzen gegenüber stressbedingungen
DE69534227D1 (de) Stoffe und verfahren zur beherrschung der hyperakuten abstossung von menschlichen transplantaten
DE69637656D1 (de) Methoden zur Züchtung von Tierzellen
DE60041821D1 (de) Pluripotent embryonale stammzellen-ähnliche zellen, zusammensetzungen und ihre vervendungen
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
EA199700004A1 (ru) Усиленная аккумуляция трегалозы в растениях
ATE330003T1 (de) Rekombinanter stabiler zellklon, seine herstellung und verwendung
BR0014519A (pt) Sequências de sinais para a preparação de leu-herudin através da secreção por e. coli no meio de cultura
DE60211772D1 (de) Verfahren zur Herstellung von Proteine
ATE486944T1 (de) Translationselongationsfaktor-promotor aus pichia pastoris und verfahren zur herstellung von rekombinantem protein unter verwendung davon
ATE517176T1 (de) Verfahren zur kultivierung von geschmackszellen aus säugern
DE602004023408D1 (de) Agments unter verwendung einer e.coli-signalsequenz sowie verfahren zur massenproduktion des antikörperfragments
EA200100023A1 (ru) Промышленный способ производства гетерологичных белков в пригодных для этого способа штаммах е.coli
ATE201908T1 (de) Verfahren zur herstellung von riboflavin mittels mikroorganismen mit veränderter isocitratlyase- aktivität
ATE378397T1 (de) Verfahren zum kultivieren von mikroorganismen unter reduzierenden bedingungen mittels einer gasströmung
ATE359359T1 (de) Myeloma zellkultur in einem transferrin-freien medium mit niedrigem eisengehalt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1543106

Country of ref document: EP

REN Ceased due to non-payment of the annual fee